873 related articles for article (PubMed ID: 23737214)
21. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.
Wilens TE; Newcorn JH; Kratochvil CJ; Gao H; Thomason CK; Rogers AK; Feldman PD; Levine LR
J Pediatr; 2006 Jul; 149(1):112-9. PubMed ID: 16860138
[TBL] [Abstract][Full Text] [Related]
22. Does atomoxetine improve executive function, inhibitory control, and hyperactivity? Results from a placebo-controlled trial using quantitative measurement technology.
Wehmeier PM; Schacht A; Ulberstad F; Lehmann M; Schneider-Fresenius C; Lehmkuhl G; Dittmann RW; Banaschewski T
J Clin Psychopharmacol; 2012 Oct; 32(5):653-60. PubMed ID: 22926599
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression.
; Bangs ME; Emslie GJ; Spencer TJ; Ramsey JL; Carlson C; Bartky EJ; Busner J; Duesenberg DA; Harshawat P; Kaplan SL; Quintana H; Allen AJ; Sumner CR
J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):407-20. PubMed ID: 17822337
[TBL] [Abstract][Full Text] [Related]
25. Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study.
Troost PW; Steenhuis MP; Tuynman-Qua HG; Kalverdijk LJ; Buitelaar JK; Minderaa RB; Hoekstra PJ
J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):611-9. PubMed ID: 17069549
[TBL] [Abstract][Full Text] [Related]
26. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
[TBL] [Abstract][Full Text] [Related]
27. Effects of Atomoxetine in Individuals with Attention-Deficit/Hyperactivity Disorder and Low-Functioning Autism Spectrum Disorder.
Kilincaslan A; Mutluer TD; Pasabeyoglu B; Tutkunkardas MD; Mukaddes NM
J Child Adolesc Psychopharmacol; 2016 Nov; 26(9):798-806. PubMed ID: 27228116
[TBL] [Abstract][Full Text] [Related]
28. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.
Wilens TE; Adler LA; Weiss MD; Michelson D; Ramsey JL; Moore RJ; Renard D; Brady KT; Trzepacz PT; Schuh LM; Ahrbecker LM; Levine LR;
Drug Alcohol Depend; 2008 Jul; 96(1-2):145-54. PubMed ID: 18403134
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder.
Biederman J; Heiligenstein JH; Faries DE; Galil N; Dittmann R; Emslie GJ; Kratochvil CJ; Laws HF; Schuh KJ;
Pediatrics; 2002 Dec; 110(6):e75. PubMed ID: 12456942
[TBL] [Abstract][Full Text] [Related]
30. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study.
Harfterkamp M; Buitelaar JK; Minderaa RB; van de Loo-Neus G; van der Gaag RJ; Hoekstra PJ
J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):194-9. PubMed ID: 23578015
[TBL] [Abstract][Full Text] [Related]
31. A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD).
Ramoz N; Boni C; Downing AM; Close SL; Peters SL; Prokop AM; Allen AJ; Hamon M; Purper-Ouakil D; Gorwood P
Neuropsychopharmacology; 2009 Aug; 34(9):2135-42. PubMed ID: 19387424
[TBL] [Abstract][Full Text] [Related]
32. Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder.
Chang K; Nayar D; Howe M; Rana M
J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):547-51. PubMed ID: 19877979
[TBL] [Abstract][Full Text] [Related]
33. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.
Klassen AF; Miller A; Fine S
Pediatrics; 2004 Nov; 114(5):e541-7. PubMed ID: 15520087
[TBL] [Abstract][Full Text] [Related]
34. A meta-analysis of the consistency of atomoxetine treatment effects in pediatric patients with attention-deficit/hyperactivity disorder from 15 clinical trials across four geographic regions.
Tanaka Y; Rohde LA; Jin L; Feldman PD; Upadhyaya HP
J Child Adolesc Psychopharmacol; 2013 May; 23(4):262-70. PubMed ID: 23683141
[TBL] [Abstract][Full Text] [Related]
35. Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated Database.
De Bruyckere K; Bushe C; Bartel C; Berggren L; Kan CC; Dittmann RW
CNS Drugs; 2016 Jun; 30(6):541-58. PubMed ID: 27224994
[TBL] [Abstract][Full Text] [Related]
36. Atomoxetine and neuropsychological function in children with attention-deficit/hyperactivity disorder: results of a pilot study.
Maziade M; Rouleau N; Lee B; Rogers A; Davis L; Dickson R
J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):709-18. PubMed ID: 20035589
[TBL] [Abstract][Full Text] [Related]
37. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
Gibson AP; Bettinger TL; Patel NC; Crismon ML
Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655
[TBL] [Abstract][Full Text] [Related]
38. Atomoxetine for attention deficit hyperactivity disorder in mental retardation.
Fernández-Jaén A; Fernández-Mayoralas DM; Calleja Pérez B; Muñoz Jareño N; Campos Díaz Mdel R
Pediatr Neurol; 2010 Nov; 43(5):341-7. PubMed ID: 20933178
[TBL] [Abstract][Full Text] [Related]
39. [Atomoxetine safety and efficacy in children with attention deficit/hyperactivity disorder (ADHD): initial phase of 10-week treatment in a relapse prevention study with a Spanish sample].
Escobar R; Soutullo C; San Sebastián J; Fernández E; Julián I; Lahortiga F
Actas Esp Psiquiatr; 2005; 33(1):26-32. PubMed ID: 15704028
[TBL] [Abstract][Full Text] [Related]
40. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
Schulz KP; Fan J; Bédard AC; Clerkin SM; Ivanov I; Tang CY; Halperin JM; Newcorn JH
Arch Gen Psychiatry; 2012 Sep; 69(9):952-61. PubMed ID: 22945622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]